Breaking AI & Tech News Analyzed

Lead: AI Filmmaking Breaks Free from Traditional GatekeepersZack London describes his work as “the inception of a new thing where there are no rules,” and the results are already reshaping how cinema can be produced. From a former hemstitching workshop in Stockholm, a tiny team is delivering AI‑generated sci‑fi shorts that have captured a global audience of half a billion views. Gossip Goblin’s Kitchen‑Table Production ModelThe outfit, operating under the nom de plume Gossip Goblin, uses off‑the‑shelf AI tools to write, animate and voice‑over content from a modest apartment. A typical shoot involves an actor, director and composer cramped into a studio booth to record a monologue for a Scottish‑gorilla protagonist in a transhumanist cyberpunk world. The workflow is deliberately low‑cost, with eight collaborators spread across Europe contributing remotely. Viewership Numbers Signal Rapid Audience Adoption500 million cumulative views across Instagram and YouTube (self‑reported by London).Individual shorts routinely reach several million views within days of release.High‑profile endorsements from Mathieu Kassovitz and Joe Rogan have amplified reach. Industry Reaction: Hollywood’s Growing Appetite and Critics’ BacklashMajor LA talent agents, studios and streaming platforms are dispatching representatives to Stockholm, eager to explore collaborations. At the same time, a vocal chorus of filmmakers, actors (including Elton John, Scarlett Johansson) and creators such as Vince Gilligan condemn AI‑generated content as “copyright theft” and “creative sludge.” The debate intensifies as award bodies like the Oscars and Cannes have recently barred AI works from competition. Future Outlook: Legal Grey Zones and the Next Wave of AI‑Generated CinemaLondon argues that the “grey goo” of model training makes authorship attribution murky, suggesting the industry must develop new standards for demonstrating sufficient creative input. As more Hollywood talent experiments with AI characters—e.g., AI‑generated versions of Val Kilmer—the sector is likely to confront regulatory scrutiny while continuing to push the boundaries of low‑budget, high‑impact storytelling.

The Media Revolution The news industry is once again experiencing a revolution, one that is reshaping news for a new generation of consumers. This disruption transcends all news brands, impacting all journalists and all journalism, everywhere. The Shift in Consumer Behavior We're witnessing a significant shift in how consumers access news. TV news audiences have declined by nearly 4 million people in the past five years, while YouTube has seen a trebling of its news audience and TikTok a 10-fold increase. This shift is not just about platforms; it's about the rise of independent journalists and personalities. The Rise of Creator Journalism Independent journalists like Joe Rogan, Piers Morgan, and Emily Maitlis have built massive audiences on platforms like YouTube and Substack. Joe Rogan has 20.9m subscribers on YouTube, while Piers Morgan's Uncensored YouTube channel has gained significant traction. This creator journalism is not a sideshow; it's becoming the main event. The Data Analysis The global podcast market is projected to grow from $32bn to $114bn by 2030. The UK is Substack's second-largest and fastest-growing market, with over half a million people paying subscriptions directly to writers. The Impact Analysis This revolution matters because it's driven by commentary and conversation, and the established media has yet to break into this new world at scale. The challenge is clear: will we wake up to the existential nature of this great shift in our industry, or will we be left behind? The Prediction The established news media has everything it needs to succeed in this new world, including talented journalists, experienced experts, and brands that have meaning for audiences. However, success is conditional on whether the established media is willing to deploy those assets to win and not be left behind. The priorities are clear: restore trust, reconnect through authenticity, and reinvent the newsroom.

The Rise of Louis Mosley as Palantir's Public Face The hall was packed with rightwing radicals when Louis Mosley heralded a coming revolution. Just as Oliver Cromwell – that “crusader for Christ and liberty” – routed King Charles I’s royalists, “a similar revolution is brewing today”, said the UK and Europe boss of Palantir. Globalism’s “twilight” was upon us, he said in a speech dotted with admiring mentions of the podcaster Joe Rogan and “Elon’s Doge”. Palantir's Controversial Stance and Mosley's Role It was not a typical peroration for a big UK government contractor with more than £600m in deals with the NHS, the Ministry of Defence and police. But Palantir, the world’s most controversial tech company, is no typical contractor. In recent years it has gained firm footholds across Britain’s public sector while appalling critics with its leadership’s rightwing rhetoric and its work for the US and Israeli militaries and Donald Trump’s ICE immigration crackdown. Mosley's Background and Connection to Palantir Mosley is an important figure at Palantir. He is not trained as a technologist, but worked in Tory politics, including spells as an assistant to Rory Stewart and as a councillor in the Royal Borough of Kensington and Chelsea. He read history at Oxford where he met his wife, Nura Khan, a fashion editor, with whom he has four children. He is more likely to be seen reading biographies – Aneurin Bevan and Stalin have been recent subjects – than coding manuals. The Challenges Facing Mosley and Palantir Calls are growing for Keir Starmer’s government to cut its ties with the company that was co-founded by the Trump-backing tech billionaire Peter Thiel. It means Mosley has become a lightning rod for public fear of a US tech takeover of the British state. It has fallen to him to fight back. Almost daily his boyish features can be seen defending Palantir against its critics on X.com, on podcasts and on BBC News sofas. The Future of Palantir and Mosley's Role Mosley has embraced the foundational idea of Palantir, launched after 9/11 to help the US win the war on terror. It was named after the all-seeing crystal stones from The Lord of the Rings, which, as Mosley later explained, “are made by the goodies – by elves – but they fall into the hands of the baddies – the wizards – and they get used for evil purposes”. It is, said Mosley, a constant reminder that “you’re building a very, very powerful tool, and in the wrong hands, very powerful tools can be extremely dangerous. But in the right hands, they can be used to do extraordinarily good things.”

President Donald Trump signed an executive order on Saturday in the Oval Office, joined by podcaster Joe Rogan, to fast‑track the federal review of psychedelic drugs such as ibogaine, aiming to broaden treatment options for serious mental illness.The ceremony highlighted Rogan’s long‑standing advocacy for ibogaine, a plant‑derived compound used by some veteran groups to address post‑traumatic stress. Rogan recounted texting Trump about the drug, to which the president replied, “Sounds great. Do you want FDA approval? Let’s do it.”Trump framed the order as a lifeline for patients: “Today’s order will ensure that people suffering from debilitating symptoms might finally have a chance to reclaim their lives and lead a happier life.” He added that successful outcomes could have “a tremendous impact.”In a brief moment of levity, Trump joked, “Can I have some, please? I’ll take some.” He quickly refocused, noting he has no time for depression and stays busy instead.The move enjoys rare bipartisan backing, despite ibogaine and other psychedelics remaining classified under the federal government’s most restrictive drug schedule.Health Secretary Robert F. Kennedy Jr. had previously pledged to ease medical access to psychedelics, a stance echoed in the new order, which directs the Department of Health and Human Services to allocate at least $50 million to states developing programs for serious mental‑health conditions.Simultaneously, the FDA is set to issue “national priority” vouchers for three psychedelic candidates. Commissioner Marty Makary said the vouchers will enable rapid approval “if they align with our national priorities.”The agency also plans the first human trials of ibogaine in the United States, overcoming earlier concerns about potential fatal heart effects.Ibogaine’s origins trace back to the Bwiti religious ceremonies in West‑Central Africa, where the plant has been used for centuries in spiritual contexts.Former Navy SEAL Marcus Luttrell, also present at the event, praised ibogaine, stating, “It absolutely changed my life for the better.”Rogan’s endorsement and the executive order have added a new dimension to Trump’s 2024 campaign narrative, even as he has publicly questioned the administration’s stance on the war with Iran.

Peptides are short chains of amino acids that naturally occur in the body, acting as hormones such as insulin, oxytocin and vasopressin, or as fragments released during protein digestion.In recent years, a wave of interest has turned these molecules into purported therapeutic agents for everything from weight loss to anti‑ageing and tissue repair. Prescription drugs like semaglutide (Wegovy) and tirzepatide (Mounjaro) are synthetic peptides that have undergone rigorous clinical testing and are approved for specific medical uses.However, a large portion of the market consists of unregulated, experimental peptides sold for self‑administration. These products often bypass the strict approval processes required for medicines, raising serious safety concerns.Who is using these products? Initially confined to a niche of powerlifters and bodybuilders in the 2010s, the audience has expanded dramatically. Influential figures such as podcaster Joe Rogan have promoted combinations like the “Wolverine stack” (BPC‑157 and TB‑500) for injury recovery, while other compounds—CJC‑1295, MK‑677, ipamorelin, and GHK‑Cu—are marketed for muscle growth and anti‑ageing. Social media platforms are now flooded with instructions on purchasing and injecting these substances.Scientific backing is scant. Reviews of the literature reveal that most experimental peptides have only been tested in animal or cell models. For example, BPC‑157 shows promise for tendon and muscle repair in pre‑clinical studies, but no randomized human trials have validated these effects. Similarly, TB‑4 and its synthetic analogue TB‑500 have demonstrated limited blood‑vessel formation in laboratory settings, yet human data are absent and both are listed as prohibited substances by the World Anti‑Doping Agency.Researchers also highlight a critical knowledge gap: dosage, frequency and treatment duration remain undefined, making self‑administration a gamble.Legal landscape in the UK is clear that peptides not classified as medicines fall outside the Medicines and Healthcare products Regulatory Agency’s (MHRA) remit. If a seller makes medicinal claims, the product must hold a marketing authorisation under the Human Medicines Regulations 2012. The MHRA warns that labeling items as “research use only” does not shield vendors from enforcement when evidence shows the products are intended for human consumption.Health risks are multi‑fold. Experts caution that benefits observed in animal studies do not guarantee safety in humans. Contamination with harmful impurities or bacterial endotoxins can trigger severe reactions, including septic shock. Injecting excess natural peptides may disrupt the body’s tightly regulated hormonal balance, potentially affecting multiple physiological pathways.There is also theoretical concern that augmenting peptide levels could accelerate tumour growth, as some cancers over‑express certain peptide pathways. While no direct cases have been documented, the possibility underscores the need for caution.Additional dangers include improper injection techniques (e.g., air embolism), unknown interactions with existing medications, and the lack of systematic monitoring of long‑term effects. As one researcher put it, “If something goes wrong, users may never notice until irreversible damage has occurred.”